Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer
ConclusionsThese results suggest that Gr and SumTLs at baseline are significantly associated with OS and PFS in R/M HNSCC patients treated with nivolumab.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | HNSCC | Immunotherapy | Skin Cancer | Squamous Cell Carcinoma | Study